| GlobalData's report, "Tuberculosis - Drug Pipeline | | | | - What's the next big thing in the global tuberculosis |
| Analysis and Market Forecasts to 2016" is an | | | | market landscape? – Identify, understand and |
| essential source of information and analysis on the | | | | capitalize. |
| global Tuberculosis (TB) drugs market. The report | | | | 1 Table of contents 3 |
| identifies the key trends shaping and driving the | | | | - 1.1 List of Tables 5 |
| global TB market. The report also provides insight | | | | - 1.2 List of Figures 5 |
| into the prevalent competitive landscape and the | | | | 2 Tuberculosis: Market Characterization 6 |
| emerging players expected to significantly alter the | | | | - 2.1 Overview 6 |
| positioning of the existing market leaders. Most | | | | - 2.2 Tuberculosis Drugs Market Size 6 |
| importantly, the report provides valuable insight into | | | | - 2.3 Tuberculosis Drugs Market Forecast and CAGR |
| the pipeline products within the global TB sector. The | | | | 7 |
| global TB drugs market was worth $99m in 2009. | | | | - 2.4 Drivers and Barriers for the Tuberculosis Drugs |
| The market is expected to decline by 2.8% during | | | | Market 8 |
| the next seven years. The TB drugs market has | | | | - 2.4.1 Drivers for the Tuberculosis drugs market 8 |
| been well served by antimycobacterial agents and | | | | - 2.4.2 Barriers for the Tuberculosis drugs market 9 |
| antibiotics since the 1960s. The cure rates have | | | | 2.5 Opportunity and Unmet Need 9 |
| improved with the conventional DOTs (Directly | | | | 2.6 Key Takeaway 11 |
| Observed Therapy). Multi-Drug Resistant Tuberculosis | | | | 3 Tuberculosis Drugs Market: Competitive |
| (MDR-TB) has been a consequence of patient | | | | Assessment 12 |
| non-compliance and the long duration of therapy. | | | | - 3.1 Overview 12 |
| Companies seem to be actively developing products | | | | - 3.2 Strategic Competitor Assessment 12 |
| for the prophylaxis and cure of TB that have lesser | | | | - 3.3 Product Profile for the Major Drugs in the |
| treatment durations. The two not-for-profit | | | | Tuberculosis 13 |
| organizations, TB Alliance and the Aeras Global TB | | | | - 3.3.1 Isoniazid (INH) 13 |
| Vaccine Foundation, have partnered with | | | | - 3.3.2 Rifampin (RIF) 13 |
| pharmaceutical players in order to address the burden | | | | - 3.3.3 Pyrazinamide (PZA) 14 |
| of TB in developed and developing nations. With the | | | | - 3.3.4 Ethambutol (EMB) 14 |
| success of the ongoing clinical studies, the market is | | | | - 3.3.5 Streptomycin (SM) and Other Aminoglycosides |
| expected to witness a breakthrough in TB control | | | | 14 |
| and treatment. The vaccines' primary focus would be | | | | - 3.3.6 Rifabutin 15 |
| to inhibit the infection at the first place. The global TB | | | | - 3.3.7 Capreomycin 15 |
| drugs market is heading towards a phase of decline | | | | 3.4 Key Takeaway 15 |
| as no launches are expected till 2016. | | | | 4 Tuberculosis Drugs Market: Pipeline Assessment 16 |
| This report is built using data and information sourced | | | | - 4.1 Overview 16 |
| from proprietary databases, primary and secondary | | | | - 4.2 Strategic Pipeline Assessment 16 |
| research and in house analysis by GlobalData's team | | | | - 4.2.1 Technology Trends Analytic Framework 16 |
| of industry experts. | | | | 4.3 Tuberculosis Therapeutics – Promising Drugs |
| Scope | | | | under Clinical Development 17 |
| The scope of the report includes: | | | | 4.4 Molecule Profile for Promising Drugs/Vaccines |
| - Annualized global Tuberculosis drugs market | | | | under Clinical Development 18 |
| revenue data from 2001 to 2009, forecast for seven | | | | - 4.4.1 Moxifloxacin (TB Alliance) 18 |
| years to 2016. | | | | - 4.4.2 MVA85A/ AERAS-485 (Oxford-Emergent |
| - Geographies covered in this report include the US | | | | Tuberculosis Consortium Ltd/Aeras) 20 |
| (United States), the UK (United Kingdom), Italy, Spain, | | | | - 4.4.3 AERAS-402/ Crucell Ad35 (AERAS/ Crucell) 21 |
| Germany, France and Japan. | | | | - 4.4.4 TMC207 (Tibotec/TB Alliance) 21 |
| - Pipeline analysis data providing a split across the | | | | - 4.4.5 GSK M72 (GlaxoSmithKline (GSK) Biologicals/ |
| different phases of development by mechanism of | | | | Aeras) 22 |
| action and emerging trends. The key classes of | | | | - 4.4.6 PA-824 (Chiron/ TB Alliance) 23 |
| mechanism of action of drugs include ATP synthase | | | | 4.5 Tuberculosis Drugs Market – Clinical Pipeline by |
| inhibitors, protein synthesis inhibitors, cell wall | | | | Mechanism of Action 24 |
| synthesis inhibitors, DNA gyrase inhibitors, FAS | | | | - 4.5.1 Tuberculosis Pipeline – Pipeline by Clinical |
| synthase inhibitors, translocase-1 inhibitors and others. | | | | Phases of Development 25 |
| The vaccine candidates have been segmented as | | | | - 4.5.2 Tuberculosis Therapeutics – Phase III |
| recombinant live vaccines, recombinant protein | | | | Clinical Pipeline 25 |
| vaccines and viral vectored vaccines. | | | | - 4.5.3 Tuberculosis Therapeutics – Phase II Clinical |
| - Analysis of the current and future market | | | | Pipeline 25 |
| competition in the global Tuberculosis drugs market. | | | | - 4.5.4 Tuberculosis Therapeutics – Phase I Clinical |
| The key market players covered are isoniazid, | | | | Pipeline 26 |
| rifampin, pyrazinamide, ethambutol, streptomycin, | | | | - 4.5.5 Tuberculosis Therapeutics – Preclinical |
| rifabutin and capreomycin. | | | | Phase Pipeline 26 |
| - Insightful review of the key industry drivers, | | | | - 4.5.6 Tuberculosis Therapeutics – Discovery |
| restraints and challenges. Each trend is independently | | | | Pipeline 26 |
| researched to provide qualitative analysis of its | | | | 4.6 Key Takeaway 26 |
| implications. | | | | 5 Tuberculosis Drugs Market: Implications for Future |
| - Key topics covered include strategic competitor | | | | Market Competition 27 |
| assessments, market characterization, the unmet | | | | 6 Tuberculosis Drugs Market: Future Players in the |
| needs and the implications for the future market | | | | Tuberculosis Market 29 |
| associated with TB. | | | | - 6.1 Introduction 29 |
| Reasons to buy | | | | - 6.2 TB Alliance, the US 30 |
| The report will enhance your decision making | | | | - 6.2.1 Overview 30 |
| capability in a more rapid and time sensitive manner. | | | | - 6.2.2 Tuberculosis Portfolio 30 |
| It will allow you to: | | | | 6.3 Aeras (Aeras Global TB Vaccine Foundation), the |
| - Develop and design your in-licensing and out-licensing | | | | US 31 |
| strategies through review of pipeline products and | | | | - 6.3.1 Overview 31 |
| technologies and by identifying companies with the | | | | - 6.3.2 Tuberculosis Portfolio 32 |
| most robust pipeline. | | | | 6.4 Crucell, the Netherlands 34 |
| - Develop business strategies by understanding the | | | | - 6.4.1 Overview 34 |
| trends shaping and driving the global tuberculosis | | | | - 6.4.2 Tuberculosis Portfolio 34 |
| market. | | | | 6.5 Tibotec BVBA, Belgium 35 |
| - Drive revenues by understanding key trends, | | | | - 6.5.1 Overview 35 |
| innovative products and technologies, market | | | | - 6.5.2 Tuberculosis Portfolio 35 |
| segments and companies likely to impact the global | | | | 7 Tuberculosis Drugs Market: Appendix 37 |
| tuberculosis market in future. | | | | - 7.1 Market Definitions 37 |
| - Formulate effective sales and marketing strategies | | | | - 7.2 Abbreviations 37 |
| by understanding the competitive landscape and by | | | | - 7.3 Research Methodology 38 |
| analyzing the performance of various competitors. | | | | - 7.3.1 Coverage 39 |
| - Identify emerging players with potentially strong | | | | - 7.3.2 Secondary Research 39 |
| product portfolio and create effective | | | | - 7.3.3 Forecasting 40 |
| counter-strategies to gain competitive advantage. | | | | - 7.3.4 Primary Research 43 |
| - Organize your sales and marketing efforts by | | | | - 7.3.5 Expert Panel Validation 43 |
| identifying the market categories and segments that | | | | 7.4 Contact Us 43 |
| present maximum opportunities for consolidations, | | | | 7.5 Disclaimer 43 |
| investments and strategic partnerships. | | | | 7. |